La malformation anévrysmale de la veine de Galien (MAVG) est une malformation vasculaire cérébrale congénitale qui représente près d’un tiers des anomalies vasculaires pédiatriques. Au sein d’une cohorte de 51 patients atteints d’une MAVG, nous avons identifié 5 individus porteurs de mutations hétérozygotes pathogéniques d’EPHB4. Ces mutations incluent une mutation tronquante survenue de novo ainsi que des mutations d’épissage et faux-sens hétérozygotes délétères héritées d’un parent. L’invalidation d’EPHB4 chez les embryons de Danio rerio est à l’origine d’anomalies vasculaires cérébrales spécifiques impliquant la veine dorsale longitudinale, la veine orthologue médiane du prosencéphale (précurseur embryonnaire de la veine de Galien). La co-injection de l’ARNm tronqué a permis la restauration d’un phénotype sauvage démontrant que le phénotype vasculaire observé est la conséquence d’une perte de fonction d’EPHB4. L’ensemble de ces données indique qu’EPHB4 est un gène déterminant chez un sous-groupe de patients atteints d’une MAVG, comme chez Danio rerio. Les mutations perte de fonction d’EPHB4 sont à l’origine d’anomalies spécifiques du développement vasculaire cérébral. L’identification de mutations pathogéniques d’EPHB4 chez des patients présentant des malformations capillaires implique une surveillance attentive de la grossesse. Cette surveillance échographique renforcée pourrait permettre la détection précoce d’une MAVG et une prise en charge anténatale et néonatale optimale. / Vein of Galen aneurysmal malformation (VGAM) is one of the most common fetal brain vascular malformations. We conducted whole exome sequencing in 19 unrelated VGAM patients and subsequently screened candidate gene in a cohort of 32 additional patients. We found 5 affected individuals with heterozygous mutations in EPHB4 including de novo frameshift or inherited deleterious splice or missense mutations predicted to be pathogenic by in silico tools. Knockdown of EPHB4 in zebrafish embryos leads to specific anomalies of dorsal cranial vessels including dorsal longitudinal vein, the ortholog of the median prosencephalic vein, the embryonic precursor of the vein of Galen. This model allowed todemonstrate EPHB4 loss of function mutations in VGAM by the ability to rescue the brain vascular defect in knockdown zebrafish co-injected with wild type but not truncated EPHB4 mimicking the frameshift mutation. Our data showed that in both species, loss of function mutations of EPHB4 result in specific and similar brain vascular development anomaliesThe identification of EPHB4 pathogenic mutation in patients presenting capillary malformation or VGAM should lead to careful follow up of pregnancy of carriers for early detection of VGAM in order to propose optimal neonatal care. Endovascular embolization indeed greatly improved the prognosis of VGAM patients.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal.

La prise d’un supplément d’acide folique en période préconceptionnelle réduit le risque d’une anomalie du tube neural (ATN), une malformation du système nerveux. Dans le but d’en réduire la prévalence, la Société des Obstétriciens et Gynécologues du Canada a émis de nouvelles directives cliniques en 2007 qui tenaient compte de différents facteurs de risque pour les ATN et pour qui la dose recommandée variait selon le profil de risque de la femme, allant de 0,4 à 5,0 mg d’acide folique. Jusqu’à présent, peu de données sont disponibles sur les effets de la prise d’une haute dose d’acide folique. Les objectifs de cette étude étaient: 1) d’évaluer la concordance entre la supplémentation en acide folique chez les femmes enceintes et les nouvelles recommandations canadiennes; 2) d’identifier les déterminants d’une utilisation concordante et 3) d’évaluer si la prise de hautes doses d’acide folique en période périconceptionnelle réduisait le risque de malformations congénitales autre que les ATN. Pour répondre à ces objectifs, une étude transversale et une étude écologique ont été effectuées. La première incluait 361 femmes enceintes recrutées aux cliniques d’obstétriques du CHU Sainte-Justine et la deuxième utilisait le Registre Québécois des Grossesses, issu du jumelage de trois banques de données administratives au Québec (RAMQ, Med-Écho et ISQ), où 152 392 couples mère-enfant ont été identifiés. Seul 27% des femmes enceintes ayant participé à l’étude transversale avaient une supplémentation en acide folique, avec ou sans ordonnance, concordante aux lignes directrices canadiennes. La concordance variait selon leur profil de facteurs de risque pour les ATN. Notre étude écologique montre que la prévalence annuelle de l’utilisation de haute dose d’acide folique (avec ordonnance) en période périconceptionnelle a augmenté de 0,17% à 0,80% (p < 0,0001) entre 1998 et 2008 et que la prévalence des malformations congénitales majeures a augmenté de 15% au cours de la même période (3,35% à 3,87%, p<0,0001). Les résultats de nos deux études montrent que l’acide folique n’est pas largement utilisé par les femmes en âge de procréer et ce, peu importe la dose. De nouvelles campagnes de santé publique devront être mises sur pied, afin d’inciter les femmes à consommer de l’acide folique avant et pendant leur grossesse. Également, la prise de haute dose d’acide folique ne semble pas avoir diminué le risque de malformations congénitales, à l’échelle populationnelle. / The use of folic acid during the preconceptionnal period reduces the risk of neural tube defects (NTD), a malformation of the nervous system. In order to reduce it’s prevalence, the Society of Obstetricians and Gynaecologists of Canada proposed new practice clinical guidelines, in 2007, on the use of pre-conceptional vitamin/folic acid supplementation for the prevention of NTDs, with specific recommendations to prevent recurrences and occurrences among women with intermediate to high health risk factors and for whom the dose was different. The objectives of this study were to evaluate the concordance between the new guidelines and folic acid use in real life; 2) to identify predictors associated with a recommended folic acid supplementation, and 3) to evaluate if the use of folic acid could reduce the risk of congenital malformations other than NTDs. A cross-sectional study and an ecological study have been conducted. 361 women were recruited in obstetrics outpatient clinic at the CHU Ste-Justine for the first study and 152,392 pregnancies and babies were identified in the Quebec Pregnancy Registry, which results from the linkage of three administrative health care databases from Quebec (RAMQ, Med-Echo and ISQ) for the second study. Only 27% of the wowen recruited for the first study had periconceptional folic acid supplementation intake that was concordant with guideline. Concordance varied according to their health risk factors profile for NTD. Our ecological study showed that the annual prevalence of periconceptional folic acid use increased from 0.17% to 0.80% (p < 0,0001) from 1998 to 2008 and birth prevalence of major congenital malformations increased by 15% (3.35% to 3.87%, p < 0,0001) during the same period. Our findings highlight the fact that folic acid is not widely used by women of childbearing age, regardless of the dose. There is a need for new public health programs to encourange women to consume folic acid every day before and during pregnancy. Moreover, the use of high dose folic acid does not seem to be correlated with a decline in the prevalence of major congenital malformations, on a populational level.

Dans le cadre du programme commun d’études pharmaco-épidémiologiques de la caisse nationale de l'assurance maladie et de l’agence nationale de sécurité du médicament, visant à évaluer l'impact sanitaire en France de l'exposition in utero à l’acide valproïque à partir des bases de données médico-administratives (BDMA) françaises, l’objectif de cette thèse était d’étudier l’utilisation des antiépileptiques pendant la grossesse et les risques de malformations congénitales et de troubles neuro-développementaux associés chez l’enfant. Le premier volet de cette thèse a consisté à formaliser et publier un algorithme d’identification des grossesses spécifiquement adapté aux BDMA françaises. L’application de cet algorithme à la description de l’utilisation des antiépileptiques pendant la grossesse a permis d’estimer à 6,7‰ la prévalence de l’utilisation des antiépileptiques pendant la grossesse et de montrer une baisse de l’utilisation des antiépileptiques de première génération, en particulier de l’acide valproïque, au bénéfice des antiépileptiques de deuxième génération entre 2007 et 2014. Dans le deuxième volet de cette thèse, l’exposition in utero à l’acide valproïque a été retrouvée associée à une augmentation du risque d’un grand nombre des malformations congénitales majeures (MCM) étudiées, avec une relation dose-effet pour les MCM les plus fréquentes, et l’exposition in utero au topiramate à une augmentation du risque de fentes oro-faciales. Des signaux relatifs à la prégabaline, au clonazépam et au phénobarbital ont aussi été identifiés. Dans le troisième volet de cette thèse, l’exposition in utero à l’acide valproïque a été retrouvée associée à une augmentation du risque de chacun des événements neuro-développementaux précoces étudiés versus lamotrigine, avec une relation dose-effet, à l’inverse des autres antiépileptiques. La réalisation d’études pharmaco-épidémiologiques à partir des BDMA françaises a permis aux autorités sanitaires de fournir rapidement des données sur l’utilisation des antiépileptiques pendant la grossesse en France. La réalisation de ces études a aussi permis de participer à l’enrichissement de la littérature observationnelle internationale sur les conséquences de l’exposition in utero aux antiépileptiques pour l’enfant à naitre. / The works of this thesis have been carried out within a programme of pharmacoepidemiological studies initiated by the National Agency of Medicine and Health Product Safety (ANSM) and the National Health Insurance fund (Cnam) in order to evaluate the public health situation in relation to prenatal exposure to valproic acid in France on the basis of the French health care databases. The objective of this thesis was to study antiepileptic drug (AED) use during pregnancy and the risks of congenital malformations and neurodevelopmental disorders associated with prenatal exposure to these drugs. In a first study, we developed an algorithm to identify pregnancy episodes and related outcomes using the French health care claims databases and applied it to study AED use during pregnancy between 2007 and 2014. Over the study period, 6.7 per 1000 pregnancies were exposed to an AED. The use of newer AEDs increased concomitantly with the decreased use of valproic acid and the other older AEDs. In a second study, prenatal exposure to valproic acid was found to be associated with a wide range of malformations among those investigated, with a dose-response relationship for half of them, and prenatal exposure to topiramate with an increased risk of cleft lip with or without cleft palate. Signals concerning pregabalin, clonazepam and phenobarbital have also been identified. In a third study, prenatal exposure to valproic acid was found to be associated with increased risks of all early neurodevelopmental outcomes investigated compared with lamotrigine, with a dose-response relationship. Prenatal exposure to the other AEDs was not associated with an increased risk of any of these neurodevelopmental outcomes versus lamotrigine. Conducting pharmacoepidemiological studies based on the French health care databases enabled the health authorities to rapidly provide data on the use of AED during pregnancy in France. It also brought additional evidence to the international observational literature on the consequences of prenatal exposure to AEDs for the unborn child.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal

La prise d’un supplément d’acide folique en période préconceptionnelle réduit le risque d’une anomalie du tube neural (ATN), une malformation du système nerveux. Dans le but d’en réduire la prévalence, la Société des Obstétriciens et Gynécologues du Canada a émis de nouvelles directives cliniques en 2007 qui tenaient compte de différents facteurs de risque pour les ATN et pour qui la dose recommandée variait selon le profil de risque de la femme, allant de 0,4 à 5,0 mg d’acide folique. Jusqu’à présent, peu de données sont disponibles sur les effets de la prise d’une haute dose d’acide folique. Les objectifs de cette étude étaient: 1) d’évaluer la concordance entre la supplémentation en acide folique chez les femmes enceintes et les nouvelles recommandations canadiennes; 2) d’identifier les déterminants d’une utilisation concordante et 3) d’évaluer si la prise de hautes doses d’acide folique en période périconceptionnelle réduisait le risque de malformations congénitales autre que les ATN. Pour répondre à ces objectifs, une étude transversale et une étude écologique ont été effectuées. La première incluait 361 femmes enceintes recrutées aux cliniques d’obstétriques du CHU Sainte-Justine et la deuxième utilisait le Registre Québécois des Grossesses, issu du jumelage de trois banques de données administratives au Québec (RAMQ, Med-Écho et ISQ), où 152 392 couples mère-enfant ont été identifiés. Seul 27% des femmes enceintes ayant participé à l’étude transversale avaient une supplémentation en acide folique, avec ou sans ordonnance, concordante aux lignes directrices canadiennes. La concordance variait selon leur profil de facteurs de risque pour les ATN. Notre étude écologique montre que la prévalence annuelle de l’utilisation de haute dose d’acide folique (avec ordonnance) en période périconceptionnelle a augmenté de 0,17% à 0,80% (p < 0,0001) entre 1998 et 2008 et que la prévalence des malformations congénitales majeures a augmenté de 15% au cours de la même période (3,35% à 3,87%, p<0,0001). Les résultats de nos deux études montrent que l’acide folique n’est pas largement utilisé par les femmes en âge de procréer et ce, peu importe la dose. De nouvelles campagnes de santé publique devront être mises sur pied, afin d’inciter les femmes à consommer de l’acide folique avant et pendant leur grossesse. Également, la prise de haute dose d’acide folique ne semble pas avoir diminué le risque de malformations congénitales, à l’échelle populationnelle. / The use of folic acid during the preconceptionnal period reduces the risk of neural tube defects (NTD), a malformation of the nervous system. In order to reduce it’s prevalence, the Society of Obstetricians and Gynaecologists of Canada proposed new practice clinical guidelines, in 2007, on the use of pre-conceptional vitamin/folic acid supplementation for the prevention of NTDs, with specific recommendations to prevent recurrences and occurrences among women with intermediate to high health risk factors and for whom the dose was different. The objectives of this study were to evaluate the concordance between the new guidelines and folic acid use in real life; 2) to identify predictors associated with a recommended folic acid supplementation, and 3) to evaluate if the use of folic acid could reduce the risk of congenital malformations other than NTDs. A cross-sectional study and an ecological study have been conducted. 361 women were recruited in obstetrics outpatient clinic at the CHU Ste-Justine for the first study and 152,392 pregnancies and babies were identified in the Quebec Pregnancy Registry, which results from the linkage of three administrative health care databases from Quebec (RAMQ, Med-Echo and ISQ) for the second study. Only 27% of the wowen recruited for the first study had periconceptional folic acid supplementation intake that was concordant with guideline. Concordance varied according to their health risk factors profile for NTD. Our ecological study showed that the annual prevalence of periconceptional folic acid use increased from 0.17% to 0.80% (p < 0,0001) from 1998 to 2008 and birth prevalence of major congenital malformations increased by 15% (3.35% to 3.87%, p < 0,0001) during the same period. Our findings highlight the fact that folic acid is not widely used by women of childbearing age, regardless of the dose. There is a need for new public health programs to encourange women to consume folic acid every day before and during pregnancy. Moreover, the use of high dose folic acid does not seem to be correlated with a decline in the prevalence of major congenital malformations, on a populational level.

L’infertilité touche environ 11 à 15 % des couples au Canada. Les modalités de la procréation médicalement assistée (PMA) incluent la stimulation ovarienne (SO), l’insémination intra-utérine (IIU) et les techniques de la reproduction assistée (TRA). Les grossesses multiples sont parmi les effets indésirables les plus communs de l’utilisation des TRA. Toutefois, il n’y a pas de consensus sur l’ampleur du risque de grossesses multiples associé à l’utilisation des modalités de la PMA. De plus, il n’est pas clair si les modalités de la PMA sont associées à un risque élevé de malformations congénitales majeures (MCM) d’un ou plusieurs systèmes et organes du corps humain. Un projet de recherche en trois volets a été développé afin de répondre à ces questions. Dans un premier volet, une étude cas-témoin a été conduite afin de quantifier le risque de naissances multiples associé à l’utilisation des modalités de la PMA. Comparativement à une conception spontanée (CS), le recours à la SO seule, l’IIU, et les TRA étaient associés à une augmentation significative de plus de quatre, neuf et 31 fois du risque de naissances multiples, respectivement. Les femmes ayant fait appel à une IIU+SO ou aux TRA avaient un risque accru de naissances multiples (odds ratio (OR)ajusté, 1,98; IC95%, 1,12-3,49; ORajusté, 6,81; IC95%, 3,72-12,49, respectivement) comparativement à l’utilisation de la SO seule. Dans un deuxième volet, une analyse cas-témoin a été conduite afin de quantifier le risque de MCM associés à l’utilisation des modalités de la PMA. Comparée à une CS, l'utilisation des TRA était associée à une augmentation du risque des malformations du système urogénitale (ORajusté, 3,11; IC95%, 1,33–7,27) et l'utilisation de l'IIU était associée à un risque accru des malformations du système musculosquelettique (ORajusté, 2,02; IC95%, 1,10–3,71). L'utilisation des TRA était associée à une augmentation du risque des malformations du système urogénitale (ORajusté, 7,18; IC95%, 1,59-32,53) par rapport à l’utilisation de la SO seule. Dans un troisième volet, les résultats de la revue systématique et méta-analyse ont démontré que l'utilisation de la SO seule et l’IIU±SO étaient associée à une augmentation significative de presque 9 fois du risque de grossesses multiples par rapport à une CS. Des augmentations similaires ont été observées suite à l’utilisation du citrate de clomifène seul. Par rapport à une CS, l'utilisation de la SO seule était associée à une augmentation significative de 48% du risque des malformations du système musculosquelettique, de 73% le risque des malformations du système nerveux, de 76% le risque de malformations congénitales du système digestif, de 68% le risque de malformations des yeux, des oreilles, du visage et du cou, et plus de deux fois le risque de malformations congénitales du système respiratoire. L'utilisation de l'IIU était associée à une augmentation significative de 52% du risque de malformations du système urogénitales et de 54% du risque de malformations musculosquelettiques par rapport à une CS. Bien que le risque de grossesses multiples associées aux TRA puisse être contrôlé par le transfert d'un embryon unique, un suivi particulier devrait être accordée au risque de grossesses multiples associé à l’utilisation des traitements n’impliquant pas un transfert d’embryons. L’effet tératogène potentiel associé à l’utilisation des modalités de la PMA doit être considéré dans la prise des décisions thérapeutiques. La mise en place d’un registre de la PMA pour la surveillance des effets périnataux indésirables devient nécessaire / Infertility affects 11 to 15% of couples in Canada. The modalities of medically assisted reproduction (MAR) include ovarian stimulation (OS), intrauterine insemination (IUI) and assisted reproduction techniques (ART). Multiple pregnancies are among the most common side effects of using ART. However, there is no consensus on the magnitude of the risk of multiple pregnancies associated with the use of MAR modalities. In addition, it is unclear whether the modalities of MAR are associated with a high risk of major congenital malformations (MCM) affecting one or more specific organ system. A three-part research project was developed to answer these questions. In the first part, a case-control study was conducted to quantify the risk of multiple births associated with the use of the three MAR modalities. Compared to spontaneous conception (SC), the use of OS alone, IUI, and ART was associated with a significant increase of more than four, nine, and 31 times the risk of multiple births, respectively. Women who used IUI with OS or ART had an increased risk of multiple births (adjusted odds ratio (OR), 1.98; 95%CI, 1.12-3.49; adjusted OR, 6.81; 95%CI, 3.72-12.49, respectively) compared to the use of OS alone. In a second part, a case-control analysis was conducted in order to quantify the risk of MCM associated with the use of MAR modalities. Compared to SC, the use of ART was associated with an increased risk of urogenital malformations (adjusted OR, 3.11; 95%CI, 1.33–7.27) and the use of IUI was associated with increased risk of musculoskeletal malformations (adjusted OR, 2.02; 95% CI, 1.10–3.71). The use of ART was associated with an increased risk of urogenital malformations (adjusted OR, 7.18; 95% CI 1.59-32.53) compared to the use of OS alone. In a third part, results of the systematic review and meta-analysis demonstrated that the use of OS alone and IUI ± OS were associated with a significant increase of nine times the risk of multiple pregnancies compared to a SC. Similar increases have been found following the use of clomiphene citrate alone. Compared to SC, the use of OS alone was associated with a significant 48% increased risk of musculoskeletal malformations, 73% increased risk of malformations of the nervous system, 76% increased risk of digestive system malformations, 68% increased risk of malformations of the eye, ear, face and neck, and more than twice the risk of congenital respiratory system malformations. The use of IUI was associated with a significant 52% increased risk of urogenital malformations and 54% increased risk of musculoskeletal malformations compared to SC. Although the risk of multiple pregnancies associated with ART can be controlled using a single embryo transfer in IVF cycles, monitoring the risk of multiple pregnancies associated with the use of treatments that do not involve embryo transfer is essential. The potential teratogenic effect associated with the use of MAR modalities should be considered when making therapeutic decisions. The establishment of a registry for the surveillance of MAR adverse perinatal outcomes becomes necessary.

O genoma humano é composto por diversos tipos de variações estruturais, como por exemplo, as variações no número de cópias (CNVs), que, mesmo sendo muito pequenas, podem gerar diversas alterações clínicas específicas, como as malformações congênitas e o atraso do desenvolvimento neuropsicomotor (MC/ADNPM). Para a detecção destas alterações existem diferentes técnicas citogenômicas dentre elas a FISH (Fluorescent in situ Hibridization) e a MLPA (Multiplex Ligation-dependent Probe Amplification), que investigam um número limitado de regiões do genoma, como as regiões envolvidas nas síndromes de microdeleções/microduplicações mais comuns e as regiões subteloméricas. Outros métodos como a cariotipagem clássica e o array genômico possibilitam uma análise completa do DNA em uma única reação, aumentando a taxa de detecção de desequilíbrios complexos. Alcançar um diagnóstico inequívoco é fundamental para entender a natureza da doença, fornecendo respostas sobre o prognóstico, sobre os riscos de recorrência e direcionando o paciente à terapia específica, o que pode minimizar o custo financeiro dessas doenças e até mesmo possibilitar a inclusão desses indivíduos na sociedade. O projeto teve como objetivo comparar a capacidade diagnóstica destas tecnologias (FISH, MLPA e array) para a elucidação etiológica de pacientes sindrômicos encaminhados para a unidade de genética. A casuística deste trabalho foi composta pela análise dos resultados das técnicas de FISH e/ou MLPA e array, utilizadas no diagnóstico de 78 pacientes com MC/ADNPM. Na técnica de FISH, empregada na análise genômica de 22 pacientes, foram utilizadas sondas locus específicas para as regiões das principais síndromes de microdeleção/microduplicação e para as regiões subteloméricas de cromossomos específicos. Por meio desta metodologia, foram identificados ~18,2% dos pacientes com diferentes alterações. Já a técnica de MLPA, utilizada no diagnóstico dos 78 pacientes, por meio dos kits para as principais síndromes de microdeleção/microduplicação e para as regiões subteloméricas, detectou ~34,6% de pacientes com diversas alterações. A técnica de array, realizada em todos os pacientes utilizando diferentes plataformas (Agilent, Affymetrix ou Illumina) apresentou uma taxa de ~42,3% de detecção de pacientes com pelo menos uma alteração patogênica e ~38,5% de pacientes com alterações benignas ou de significado clínico incerto. Ao avaliar as três técnicas concomitantemente foi verificada uma taxa de ~93,6% de concordância, apesar dos resultados não serem iguais em todos os casos e da técnica de MLPA não detectar ~66,2% das alterações em relação ao array. Os resultados obtidos corroboraram com dados da literatura, mas no geral a taxa de detecção foi superior às taxas descritas, o em que em parte pode ser devido ao critério de seleção dos pacientes, sugerindo fortemente que a hipótese clínica adequada é crucial para o sucesso da detecção de alteração. Embora o array seja a ferramenta mais eficiente para o diagnóstico de pacientes com malformações, seu uso como primeiro teste diagnóstico nem sempre é o mais apropriado devido ao seu custo elevado ou sua limitação em detectar inversões e translocações balanceadas. Portanto todas as técnicas estudadas têm suas vantagens e desvantagens, e poderão ser aplicadas em conjunto para que o diagnóstico molecular seja concluído. Dessa forma, são necessárias uma interação clínico-laboratorial e uma equipe técnica multiprofissional especializada para o direcionamento do diagnóstico molecular mais eficaz em relação ao custo-benefício / The human genome is composed of several types of structural variations, such as copy number variation (CNVs) which, although very small, can generate several specific clinical abnormalities, such as congenital malformations and developmental delay (CM/DD). To detect these changes there are different cytogenomics techniques, among them, FISH (Fluorescent in situ Hybridization) and MLPA (Multiplex Ligation-dependent Probe Amplification) that can investigate a limited number of genomic regions for example the most common microdeletion/microduplications syndromes and subtelomeric regions. Other methods such as classical karyotyping and array provide a complete DNA analysis in a single reaction, increasing the detection rate of complex imbalances. Acquire an unequivocal diagnosis is critical to understand the nature of the disease, providing answers about the prognosis, risks of recurrence and directing the patients to specific therapy, which can minimize the cost of these diseases and even allow the inclusion of these individuals in society. The objective of this project was to compare the diagnostic ability of these technologies (FISH, MLPA and array) for the etiologic diagnosis of syndromic patients referred to the clinical unit of genetics. The casuistry was composed by the results of analysis of 78 patients with CM/DD using FISH and/or MLPA and array. The FISH technique was utilized in genomic analysis for 22 patients and locus specific probes were used for regions of the microdeletion/microduplication syndromes and the subtelomeric regions of specific chromosomes. By this methodology ~18.2% of the patients were identified with different genomic changes. The MLPA technique was used in the diagnosis of 78 patients, with microdeletion/microduplication syndrome and subtelomeric regions, and detected ~34.6% of patients with several changes. The array technique was performed in all patients using different platforms (Agilent, Illumina or Affymetrix) and shows a rate of ~42.3% of detection at least one pathogenic change and ~38.5% of patients with benign or uncertain clinical significance changes. In assessment of the three techniques concomitantly was observed a rate of ~93.6% of concordance, although the results are not the same in all cases and the MLPA technique to detect ~ 66.2% of the changes in relation to the array. The results obtained corroborated with literature data, but the overall detection rate was higher than the rates described in the literature, due in part to the criteria selection of patients. Our results strongly suggesting that appropriate clinical hypothesis is crucial for successful change detection. Although the array is the most efficient tool for the diagnosis of patients with abnormalities, using this test as a first diagnostic approach is not always the most suitable tool because of the high cost or the limitation to detect inversions and balanced translocations. Therefore, all techniques studied have their advantages and disadvantages, and could be applied together for the completed molecular diagnosis. Thus, a clinical laboratory interaction and multidisciplinary skilled technicians is required for targeting the most effective molecular diagnosis in relation to cost-benefit

O genoma humano é composto por diversos tipos de variações estruturais, como por exemplo, as variações no número de cópias (CNVs), que, mesmo sendo muito pequenas, podem gerar diversas alterações clínicas específicas, como as malformações congênitas e o atraso do desenvolvimento neuropsicomotor (MC/ADNPM). Para a detecção destas alterações existem diferentes técnicas citogenômicas dentre elas a FISH (Fluorescent in situ Hibridization) e a MLPA (Multiplex Ligation-dependent Probe Amplification), que investigam um número limitado de regiões do genoma, como as regiões envolvidas nas síndromes de microdeleções/microduplicações mais comuns e as regiões subteloméricas. Outros métodos como a cariotipagem clássica e o array genômico possibilitam uma análise completa do DNA em uma única reação, aumentando a taxa de detecção de desequilíbrios complexos. Alcançar um diagnóstico inequívoco é fundamental para entender a natureza da doença, fornecendo respostas sobre o prognóstico, sobre os riscos de recorrência e direcionando o paciente à terapia específica, o que pode minimizar o custo financeiro dessas doenças e até mesmo possibilitar a inclusão desses indivíduos na sociedade. O projeto teve como objetivo comparar a capacidade diagnóstica destas tecnologias (FISH, MLPA e array) para a elucidação etiológica de pacientes sindrômicos encaminhados para a unidade de genética. A casuística deste trabalho foi composta pela análise dos resultados das técnicas de FISH e/ou MLPA e array, utilizadas no diagnóstico de 78 pacientes com MC/ADNPM. Na técnica de FISH, empregada na análise genômica de 22 pacientes, foram utilizadas sondas locus específicas para as regiões das principais síndromes de microdeleção/microduplicação e para as regiões subteloméricas de cromossomos específicos. Por meio desta metodologia, foram identificados ~18,2% dos pacientes com diferentes alterações. Já a técnica de MLPA, utilizada no diagnóstico dos 78 pacientes, por meio dos kits para as principais síndromes de microdeleção/microduplicação e para as regiões subteloméricas, detectou ~34,6% de pacientes com diversas alterações. A técnica de array, realizada em todos os pacientes utilizando diferentes plataformas (Agilent, Affymetrix ou Illumina) apresentou uma taxa de ~42,3% de detecção de pacientes com pelo menos uma alteração patogênica e ~38,5% de pacientes com alterações benignas ou de significado clínico incerto. Ao avaliar as três técnicas concomitantemente foi verificada uma taxa de ~93,6% de concordância, apesar dos resultados não serem iguais em todos os casos e da técnica de MLPA não detectar ~66,2% das alterações em relação ao array. Os resultados obtidos corroboraram com dados da literatura, mas no geral a taxa de detecção foi superior às taxas descritas, o em que em parte pode ser devido ao critério de seleção dos pacientes, sugerindo fortemente que a hipótese clínica adequada é crucial para o sucesso da detecção de alteração. Embora o array seja a ferramenta mais eficiente para o diagnóstico de pacientes com malformações, seu uso como primeiro teste diagnóstico nem sempre é o mais apropriado devido ao seu custo elevado ou sua limitação em detectar inversões e translocações balanceadas. Portanto todas as técnicas estudadas têm suas vantagens e desvantagens, e poderão ser aplicadas em conjunto para que o diagnóstico molecular seja concluído. Dessa forma, são necessárias uma interação clínico-laboratorial e uma equipe técnica multiprofissional especializada para o direcionamento do diagnóstico molecular mais eficaz em relação ao custo-benefício / The human genome is composed of several types of structural variations, such as copy number variation (CNVs) which, although very small, can generate several specific clinical abnormalities, such as congenital malformations and developmental delay (CM/DD). To detect these changes there are different cytogenomics techniques, among them, FISH (Fluorescent in situ Hybridization) and MLPA (Multiplex Ligation-dependent Probe Amplification) that can investigate a limited number of genomic regions for example the most common microdeletion/microduplications syndromes and subtelomeric regions. Other methods such as classical karyotyping and array provide a complete DNA analysis in a single reaction, increasing the detection rate of complex imbalances. Acquire an unequivocal diagnosis is critical to understand the nature of the disease, providing answers about the prognosis, risks of recurrence and directing the patients to specific therapy, which can minimize the cost of these diseases and even allow the inclusion of these individuals in society. The objective of this project was to compare the diagnostic ability of these technologies (FISH, MLPA and array) for the etiologic diagnosis of syndromic patients referred to the clinical unit of genetics. The casuistry was composed by the results of analysis of 78 patients with CM/DD using FISH and/or MLPA and array. The FISH technique was utilized in genomic analysis for 22 patients and locus specific probes were used for regions of the microdeletion/microduplication syndromes and the subtelomeric regions of specific chromosomes. By this methodology ~18.2% of the patients were identified with different genomic changes. The MLPA technique was used in the diagnosis of 78 patients, with microdeletion/microduplication syndrome and subtelomeric regions, and detected ~34.6% of patients with several changes. The array technique was performed in all patients using different platforms (Agilent, Illumina or Affymetrix) and shows a rate of ~42.3% of detection at least one pathogenic change and ~38.5% of patients with benign or uncertain clinical significance changes. In assessment of the three techniques concomitantly was observed a rate of ~93.6% of concordance, although the results are not the same in all cases and the MLPA technique to detect ~ 66.2% of the changes in relation to the array. The results obtained corroborated with literature data, but the overall detection rate was higher than the rates described in the literature, due in part to the criteria selection of patients. Our results strongly suggesting that appropriate clinical hypothesis is crucial for successful change detection. Although the array is the most efficient tool for the diagnosis of patients with abnormalities, using this test as a first diagnostic approach is not always the most suitable tool because of the high cost or the limitation to detect inversions and balanced translocations. Therefore, all techniques studied have their advantages and disadvantages, and could be applied together for the completed molecular diagnosis. Thus, a clinical laboratory interaction and multidisciplinary skilled technicians is required for targeting the most effective molecular diagnosis in relation to cost-benefit

Mechanisms underlying congenital malformations are largely unknown despite its high incidence, affecting 2-3% of liveborn infants. A broader knowledge about the causes of birth defects would provide valuable information regarding the outcome and prognosis of the anomaly, the development and establishment of diagnostic protocols, the design of therapeutic strategies and genetic counseling to the family. Different approaches have been used in the present thesis regarding technologies and model diseases to elucidate the contribution of genetic and epigenetic alterations in the etiopathogenesis of congenital malformations. Copy number variations, methylation patterns, as well as point mutations have been explored. Moreover, a study to analyze genetic counseling in relation to one of the new molecular techniques used has been performed. Obtained data reveal a relevant role of genetic and epigenetic alterations in congenital malformations, in some cases as a unique cause to explain the disease and in others as part of an oligogenic or multifactorial model. / Els mecanismes causants de les malformacions congènites són poc coneguts malgrat l’elevada incidència d’aquestes patologies, que afecten el 2-3% de recent nascuts. Un coneixement més ampli de les causes de les anomalies congènites proporcionaria informació rellevant pel que fa al pronòstic de l’anomalia, el desenvolupament i establiment de protocols diagnòstics, el disseny d’estratègies terapèutiques, així com l’assessorament genètic a la família. En la tesi que es presenta s’han utilitzat diferents estratègies, pel que fa a tecnologies i models de malalties, amb l’objectiu d’esbrinar la contribució d’alteracions genètiques i epigenètiques en l’etiopatogènia de les malformacions congènites. S’han analitzat variacions en número de còpia, patrons de metilació, així com mutacions puntuals. D’altra banda, també s’ha realitzat un estudi per aprofundir en l’assessorament genètic en relació a una de les noves tècniques moleculars utilitzades. Els resultats obtinguts indiquen que les altercacions genètiques i epigenètiques tenen una contribució molt rellevant en l’etiologia de les malformacions congènites, en alguns casos com a causa única de la malaltia i en altres com a component d’un model oligogènic o multifactorial.